After the 3rd cycle, the prevalence of dislipidemia such as the TC, TG and LDL-C in the breast cancers, in patients treated with cyclophosphamid, in patients treated with AC regimen were higher than in patients with colon cancer, in patients treated with 5FU, in patients treated with FOLFOX regimen, with respectively statistically significant differences.